Comparison of Early-Phase 11C-Deuterium-l-Deprenyl and 11C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease

Elena Rodriguez-Vieitez, Stephen F Carter, Konstantinos Chiotis, Laure Saint-Aubert, Antoine Leuzy, Michael Schöll, Ove Almkvist, Anders Wall, Bengt Långström, Agneta Nordberg

Research output: Contribution to journalArticlepeer-review


UNLABELLED: The PET tracer (11)C-deuterium-L-deprenyl ((11)C-DED) has been used to visualize activated astrocytes in vivo in patients with Alzheimer disease (AD). In this multitracer PET study, early-phase (11)C-DED and (11)C-Pittsburgh compound B ((11)C-PiB) (eDED and ePiB, respectively) were compared as surrogate markers of brain perfusion, and the extent to which (11)C-DED binding is influenced by brain perfusion was investigated.

METHODS: (11)C-DED, (11)C-PiB, and (18)F-FDG dynamic PET scans were obtained in age-matched groups comprising AD patients (n = 8), patients with mild cognitive impairment (n = 17), and healthy controls (n = 16). A modified reference Patlak model was used to quantify (11)C-DED binding. A simplified reference tissue model was applied to both (11)C-DED and (11)C-PiB to measure brain perfusion relative to the cerebellar gray matter (R1) and binding potentials. (11)C-PiB retention and (18)F-FDG uptake were also quantified as target-to-pons SUV ratios in 12 regions of interest (ROIs).

RESULTS: The strongest within-subject correlations with the corresponding R1 values (R1,DED and R1,PiB, respectively) and with (18)F-FDG uptake were obtained when the eDED and ePiB PET data were measured 1-4 min after injection. The optimum eDED/ePiB intervals also showed strong, significant ROI-based intersubject Pearson correlations with R1,DED/R1,PiB and with (18)F-FDG uptake, whereas (11)C-DED binding was largely independent of brain perfusion, as measured by eDED. Corresponding voxelwise correlations confirmed the ROI-based results. Temporoparietal eDED or ePiB brain perfusion measurements were highly discriminative between patient and control groups, with discriminative ability statistically comparable to that of temporoparietal (18)F-FDG glucose metabolism. Hypometabolism extended over wider regions than hypoperfusion in patient groups compared with controls.

CONCLUSION: The 1- to 4-min early-frame intervals of (11)C-DED or (11)C-PiB are suitable surrogate measures for brain perfusion. (11)C-DED binding is independent of brain perfusion, and thus (11)C-DED PET can provide information on both functional (brain perfusion) and pathologic (astrocytosis) aspects from a single PET scan. In comparison with glucose metabolism, early-phase (11)C-DED and (11)C-PiB perfusion appear to provide complementary rather than redundant information.

Original languageEnglish
Pages (from-to)1071-7
Number of pages7
JournalJournal of nuclear medicine : official publication, Society of Nuclear Medicine
Issue number7
Early online date16 Feb 2016
Publication statusPublished - Jul 2016


  • Aged
  • Alzheimer Disease
  • Aniline Compounds
  • Cerebellum
  • Cerebrovascular Circulation
  • Cognitive Dysfunction
  • Deuterium
  • Diagnosis, Differential
  • Female
  • Fluorodeoxyglucose F18
  • Gliosis
  • Gray Matter
  • Humans
  • Image Processing, Computer-Assisted
  • Male
  • Middle Aged
  • Perfusion
  • Pons
  • Positron-Emission Tomography
  • Radiopharmaceuticals
  • Selegiline
  • Thiazoles
  • Journal Article


Dive into the research topics of 'Comparison of Early-Phase 11C-Deuterium-l-Deprenyl and 11C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease'. Together they form a unique fingerprint.

Cite this